Catalyst Pharmaceuticals(CPRX)
Focus: Catalyst Pharmaceuticals is a public specialty pharma company focused on small-molecule treatments for neurology and addiction-related disorders, with significant commercial scale driven by its flagship FIRDAPSE franchise.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
5
Should You Work at Catalyst Pharmaceuticals?
AI assessmentCatalyst offers near-term career stability and growth opportunities in a consolidating company, but the Angelini acquisition introduces medium-term restructuring risk—best for those comfortable with transition or seeking a platform acquirer exit.
Why Work Here
- Strong cash position ($518M in FY2025) and 86% revenue growth YoY (from $214M to $398M) provides stability and investment capacity for ambitious projects.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$398M
Key Products
$146M Part DStable
Peak10.5yr
Core revenue driver (67% of sales) with potassium channel blockade mechanism; patent protection through 2037 provides long runway but concentration risk persists.
Help build intelligence for Catalyst Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.